Metabolic & Incretin
GLP-1, GIP, glucagon and amylin pathway compounds.
12 products
MetabolicTR5Tirzepatide
Tirzepatide is a synthetic peptide that activates both the GIP and GLP-1 receptors. Researchers study it to understand how combined incretin receptor signaling affects glucose control, body weight, and related metabolic outcomes.
10 sizes · 5mg–100mg- MetabolicRT5
Retatrutide
Retatrutide is an investigational single peptide that activates the GIP, GLP-1, and glucagon receptors. Researchers study it to test whether adding glucagon receptor activity to incretin agonism increases weight reduction and metabolic effects.
8 sizes · 5mg–60mg - MetabolicSM2
Semaglutide
Semaglutide is a long-acting analogue of human GLP-1. It is one of the most extensively studied incretin-based compounds, with large trials in type 2 diabetes, obesity, and cardiovascular outcomes.
6 sizes · 2mg–30mg - MetabolicCGL5
Cagrilintide
Cagrilintide is an investigational long-acting analogue of amylin, a pancreatic hormone involved in satiety. Researchers study it alone and with semaglutide to examine amylin receptor pathways in body-weight regulation.
2 sizes · 5mg–10mg - MetabolicCS10
Cagrilintide 5mg + Semaglutide 5mg
This item pairs cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist. The same pairing, known as CagriSema, has been studied in phase 3 trials in obesity and type 2 diabetes.
10mg*10vials - MetabolicSUR10
Survodutide
Survodutide is an investigational peptide that activates both the glucagon and GLP-1 receptors. Researchers study it in obesity and in metabolic dysfunction-associated steatohepatitis (MASH), where hepatic glucagon signaling is of particular interest.
10mg*10vials - MetabolicMTD5
Mazdutide
Mazdutide is a peptide that activates both the GLP-1 and glucagon receptors. It is approved in China for chronic weight management and has been studied in obesity and type 2 diabetes.
2 sizes · 5mg–10mg - MetabolicERA5
Eloralintide
Eloralintide is an investigational long-acting peptide that preferentially activates amylin receptors over the calcitonin receptor. Researchers study it to test whether amylin receptor selectivity affects weight reduction and tolerability in obesity.
2 sizes · 5mg–10mg - MetabolicNVG5
1-Bioglutide / NA931
NA-931 is an investigational compound from Biomed Industries described as a quadruple agonist of the IGF-1, GLP-1, GIP, and glucagon receptors. It has been tested in a registered phase 2 obesity trial.
2 sizes · 5mg–10ml - Metabolic5AD
AOD
AOD-9604 is a synthetic 16-amino-acid peptide based on the C-terminal region of human growth hormone. It was studied for effects on fat metabolism without the growth-promoting and glucose-raising actions of intact growth hormone.
2 sizes · 5mg–10ml - Metabolic5AM
5-Amino-1MQ
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme linked to fat tissue metabolism and NAD+ levels. It has been studied in mouse models of obesity and muscle aging.
3 sizes · 5mg–50mg - MetabolicSLK5
SLU-PP-332
SLU-PP-332 is a synthetic small molecule that activates the estrogen-related receptors ERRα, ERRβ, and ERRγ. It has been studied in mice as an exercise mimetic that increases oxidative metabolism.
2 sizes · 5mg–10mg